Michelle Werner

Michelle Werner, CEO of Alltrna and advocate for rare disease treatments, shares her journey from big pharma to biotech, fueled by her child's diagnosis. She explains the revolutionary potential of engineered tRNA therapy, emphasizing its ability to address countless rare genetic diseases. The conversation dives into the innovative use of AI for drug optimization and the challenges of using lipid nanoparticles for effective tRNA delivery. Michelle also highlights the importance of support networks for women leaders in biotech and the significance of storytelling in patient advocacy.

Michelle Werner, CEO of Alltrna and CEO-Partner at Flagship Pioneering, discusses her transition from R&D to commercial in the biotech industry and the impact of business school. They dive into the potential of tRNA as a treatment modality, recent progress of Alterna, navigating capital markets, and being an authentic leader.